Pharmaceuticals

The Neurodegenerative Disease Market Is Evolving Due To Rising Cancer Incidence Fuels Growth In The Capecitabine

May 1, 2026May 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

From Its 2026 Market Size, What Value Is The Neurodegenerative Disease Market Projected To Reach By 2030?

The neurodegenerative disease market size has experienced robust expansion in recent years. It is projected to expand from $57.23 billion in 2025 to $62.59 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.4%. Historically, this growth has been influenced by a combination of factors including a growing aging population and increasing healthcare infrastructure for neurology, alongside prevailing limitations such as a restricted understanding of disease pathology, reliance on conventional symptomatic treatments, and limited availability of advanced diagnostic tools.

The neurodegenerative disease market is projected to experience substantial expansion in the coming years. It is anticipated to reach $88.5 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.0%. This growth during the forecast period can be attributed to several factors, including breakthroughs in gene and cell therapy, increased research and development efforts into innovative neuroprotective drugs, the expansion of clinical trial networks, the incorporation of AI for precise early diagnosis and continuous patient monitoring, and the growing embrace of personalized medicine strategies. Key trends anticipated for the forecast period encompass the escalating prevalence of neurodegenerative disorders, augmented investment in drug development and clinical trials, the uptake of targeted and individualized therapies, enhanced awareness and early diagnostic initiatives, and the broadening availability of home-based and outpatient care options.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24618&type=smp

Which Drivers Are Supporting The Neurodegenerative Disease Market Growth?

The future expansion of the neurodegenerative disease market is anticipated to be driven by a surge in research endeavors and clinical trials. These trials involve investigative studies carried out with human participants to assess the safety, effectiveness, and possible adverse reactions of novel therapies, medications, or medical equipment. The primary catalyst behind the rise in research and clinical trials is the growing need for new treatments to meet evolving healthcare requirements and enhance patient results. Specifically for neurodegenerative diseases, clinical trials aid research by supplying essential data regarding the safety and efficacy of emerging treatments, thus facilitating therapeutic progress and improving patient prognoses. For example, a report from December 2024 by the UK-based Association of the British Pharmaceutical Industry (ABPI) indicated that the number of UK industry clinical trials started increased by 3.7% in 2023 compared to 2022. Consequently, the growing volume of research and clinical trials is projected to fuel the growth of the neurodegenerative disease market.

Which Segments Define The Neurodegenerative Disease Market Segment Structure?

The neurodegenerative disease market covered in this report is segmented –

1) By Disease Type: Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis, Huntington Disease, Amyotrophic Lateral Sclerosis

2) By Drug Type: N-methyl-D-aspartate Receptor antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs, Acetylcholinesterase (AChE) Inhibitors, Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor, Catechol-O-Methyltransferase (COMT) Inhibitor, Selective Serotonin Reuptake Inhibitor (SSRIs), Other Drug Types

3) By Route of Administration: Oral, Injectable, Transdermal, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

5) By End-User: Hospital, Retail, Online

Subsegments:

1) By Parkinson’s Disease: Idiopathic Parkinson’s Disease, Familial Parkinson’s Disease, Early-Onset Parkinson’s Disease, Parkinsonism

2) By Alzheimer’s Disease: Early-Onset Alzheimer’s Disease, Late-Onset Alzheimer’s Disease, Familial Alzheimer’s Disease (FAD), Inflammatory Subtype, Non-Inflammatory Subtype, Cortical Subtype

3) By Multiple Sclerosis (MS): Clinically Isolated Syndrome (CIS), Relapsing-Remitting MS (RRMS), Secondary Progressive MS (SPMS), Primary Progressive MS (PPMS), Progressive-Relapsing MS (PRMS)

4) By Huntington’s Disease: Adult-Onset Huntington’s Disease, Juvenile Huntington’s Disease

5) By Amyotrophic Lateral Sclerosis (ALS): Classical ALS, Limb-Onset ALS, Bulbar-Onset ALS, Respiratory-Onset ALS, Primary Lateral Sclerosis (PLS), Progressive Muscular Atrophy (PMA), Juvenile ALS, ALS-Parkinsonism-Dementia Complex (ALS-PDC)

What Trends Are Influencing The Evolution Of The Neurodegenerative Disease Market?

Leading companies within the neurodegenerative disease market are concentrating on developing innovative products, such as next-generation adaptive Deep Brain Stimulation (aDBS) systems, aiming to enhance treatment precision, bolster disease-modifying effects, and elevate patient quality of life. These next-generation adaptive deep brain stimulation (aDBS) systems are advanced neurostimulation devices engineered to deliver real-time, personalized treatment for Parkinson’s disease by dynamically adjusting stimulation parameters based on neural feedback, optimizing therapeutic effects, and minimizing side effects for improved patient outcomes. For instance, in February 2025, Medtronic, a US-based medical technology company, received approval from the U.S. Food and Drug Administration (USFDA) for the world’s first adaptive deep brain stimulation (aDBS) system for Parkinson’s disease. This approval pertains to the premarket approval (PMA) application for the Percept RC neurostimulator with BrainSense technology, which automatically adjusts therapy in response to a patient’s brain signals. The system is clinically validated to provide symptom relief for advanced Parkinson’s disease patients and signifies a significant advancement in personalized neuromodulation therapies.

Who Are The Established Players Within The Neurodegenerative Disease Market?

Major companies operating in the neurodegenerative disease market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, AbbVie Inc., Sanofi S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck & Co. Inc., Biogen Inc., Neurocrine Biosciences Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Cassava Sciences Inc., Denali Therapeutics Inc., Voyager Therapeutics Inc., AC Immune SA, Amylyx Pharmaceuticals Inc., Sage Therapeutics Inc., Alzheon Inc.

Get The Full Neurodegenerative Disease Market Report:

https://www.thebusinessresearchcompany.com/report/neurodegenerative-disease-global-market-report

Which Region Leads The Neurodegenerative Disease Market In Terms Of Market Share?

North America was the largest region in the neurodegenerative disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurodegenerative disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Neurodegenerative Disease Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/neurodegenerative-disease-global-market-report

Browse Through More Reports Similar to the Global Neurodegenerative Disease Market 2026, By The Business Research Company

Rare Neurological Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-neurological-disease-treatment-global-market-report

Degenerative Disc Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/degenerative-disc-disease-treatment-global-market-report

Neurological Disorder Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795